Therapy News and Research

RSS

Biomaterials may heal chronic diabetic wounds

Biomaterials may prove key to healing chronic wounds in Diabetic patients, delegates will hear today at the 24th European Conference on Biomaterials. Over 950 delegates are at the event in Dublin, which is jointly hosted by NUI Galway's Network of Excellence for Functional Biomaterials and the University of Ulster, Jordanstown.

7 Sep 2011

London scientist hopes to improve diagnosis for Jeune syndrome

A London scientist is hoping a new study funded by children's charity Action Medical Research, will help to improve diagnosis and work towards new treatments for a rare, incurable genetic disorder called Jeune syndrome.

7 Sep 2011

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.

7 Sep 2011

Scientists uncover new ways to stimulate pancreatic beta cell growth

One of the holy grails in diabetes research is to discover molecules that stimulate beta cell growth and to find drugs that target these molecules. Now, JDRF-funded researchers in collaboration with the pharmaceutical company Hoffmann-La Roche, have done both, discovering not only a protein that regulates beta cell growth, but also a chemical compound that stimulates it.

7 Sep 2011

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received the industry's first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine.

7 Sep 2011

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke.

6 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

AMT, NIH enter exclusive license agreement for use of AAV5-based gene therapy vectors

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.

6 Sep 2011

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Using a strategy based on treating cancer cells that carry a specific genetic signature - hyper-expression of the protein Myc - with therapy that affects the stability of the cell's DNA, more effective results can be achieved.

5 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Stem cell therapy for baldness

Researchers have found that molecular signals from stem cells within the skin's fatty layer trigger hair growth in mice. This could mean new treatments for baldness in people.

5 Sep 2011

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

A bacterial strain that specifically targets tumours could soon be used as a vehicle to deliver drugs in frontline cancer therapy. The strain is expected to be tested in cancer patients in 2013 says a scientist at the Society for General Microbiology's Autumn Conference at the University of York.

5 Sep 2011

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that a group of certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

SmokingPaST Framework tool calculates impact of investments in tobacco treatment programs

The newly released Smoking Prevalence, Savings, and Treatment (SmokingPaST) Framework is a tool designed to calculate the impact of investments in tobacco treatment programs on health and medical cost savings.

3 Sep 2011

Inhibiting the ability of immune cells to use fatty acids slows MS progression

In a paper published today in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model of multiple sclerosis.

3 Sep 2011

ATS issues guidelines on use of FENO in different clinical settings

The American Thoracic Society has issued the first-ever guidelines on the use of fractional exhaled nitric oxide (FENO) that address when to use FENO and how to interpret FENO levels in different clinical settings.

3 Sep 2011

Therapy News and Research

Biomaterials may heal chronic diabetic wounds

London scientist hopes to improve diagnosis for Jeune syndrome

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

Scientists uncover new ways to stimulate pancreatic beta cell growth

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

NINDS awards NeuroSigma STTR Phase I grant to support development of eTNS therapy for epilepsy

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

AMT, NIH enter exclusive license agreement for use of AAV5-based gene therapy vectors

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Stem cell therapy for baldness

C. sporogenes bacterium could be used as vehicle to deliver drugs in frontline cancer therapy

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

SmokingPaST Framework tool calculates impact of investments in tobacco treatment programs

Inhibiting the ability of immune cells to use fatty acids slows MS progression

ATS issues guidelines on use of FENO in different clinical settings

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News